YD Biolabs
Hsinchu, Taiwan· Est.
YD BioLabs provides sustainable, enzymatic DNA synthesis and labeling tools that streamline molecular research and therapeutic development.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
YD BioLabs provides sustainable, enzymatic DNA synthesis and labeling tools that streamline molecular research and therapeutic development.
Technology Platform
Proprietary enzymatic DNA synthesis (NGDS) that adds single 3′‑blocked nucleotides in a water‑based cycle, coupled with automated labeling (ATHENA) and antibody‑oligonucleotide conjugation (AOC).
Opportunities
Growing demand for sustainable, high‑throughput nucleic‑acid synthesis in biotech and diagnostics offers scalable market potential.
Risk Factors
Technical scaling challenges and competition from established chemical and emerging enzymatic synthesis providers could limit market penetration.
Competitive Landscape
Competes with traditional chemical synthesis firms (IDT, Thermo Fisher) and enzymatic platforms (DNA Script, Twist); differentiation lies in eco‑friendly, low‑waste processes and integrated labeling solutions.